Navigation Links
VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
Date:10/25/2007

BOSTON October 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE (lisdexamfetamine dimesylate), the first prodrug stimulant. Findings from this phase III pivotal trial were presented today at a national psychiatric meeting in Boston, Mass.

Adults with ADHD may experience significant impairments in their ability to focus, and organize and complete tasks, which could affect their work, family life and personal relationships, said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD Program at New York University School of Medicine and author of Scattered Minds: Help and Hope for Adults with ADHD. The results of this study demonstrated that VYVANSE significantly improved the core symptoms of ADHD in adult study patients.

Results of Phase III Pivotal Trial

In this double-blind, placebo-controlled, four-week study with dose escalations in 414 adults aged 18 to 55 years, treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) was significantly more effective than placebo and improvements were observed in the first week of the study.

All doses of VYVANSE showed significant improvements in the average change in ADHD Rating Scale (ADHD-RS-IV) scores, as measured from the studys start to end, the primary endpoint of this study. ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing their response to treatment. The scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, a publication of the American Psychiatric Association.

VYVA
'/>"/>

Contact: Jacelyn Seng
212-601-8385
Porter Novelli
Source:Eurekalert

Page: 1 2

Related medicine news :

1. VYVANSE(TM) Drug for the Treatment of ADHD in Adults
2. Man against HIV – new vaccine ready for human trials
3. FDA approves Phase 0 trial which tests experimental drugs on humans
4. Male contraceptive in trial
5. How do patients benefit of clinical trials
6. Glenmark’s new molecule to go through trial
7. Clinical trials need to be more frank
8. First head-to-head trials of once weekly Fosamax and Actonel therapies
9. Hormone Replacement Therapy increases the risk of endometrial cancer
10. Atrial fibrillation predicts for acute ischaemic stroke
11. Spray on contraceptive clears Phase I trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/27/2015)... March 27, 2015 Wellness for Cancer–the ... business criteria for the spa and wellness industry–has certified ... who have experienced or are living with cancer. ... Wellness 365® Network, will be identified with a special ... a provider of safe, therapeutic services for cancer patients. ...
(Date:3/27/2015)... Bleeding is one of the ... intervention (PCI), resulting in increased mortality, morbidity, and ... in which the highest-risk PCI patients with the ... often with bleeding avoidance strategies than lower-risk patients. ... Heart Institute asked the question whether prospectively determining ...
(Date:3/27/2015)... The report “CountryFocus Healthcare, Regulatory and ... of information on and analysis of the healthcare, ... elderly population and its associated disease burden are ... the elderly accounted for 27.1% of the total ... Rate (CAGR) of 1.2% to 29.5% in 2020. ...
(Date:3/27/2015)... Michigan (PRWEB) March 27, 2015 ... LiveToBeSober.org, along with former Detroit Lions wide receiver ... luncheon and educational presentation on substance abuse, treatment ... Among those who attended were pastors, ministers and ... leaders and other distinguished guests. , “Our ‘Fighting ...
Breaking Medicine News(10 mins):Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2
... , , WOONSOCKET, ... keep Americans healthy this flu season, CVS Caremark today announced its ... The program will include on-site flu clinics at One-Stop Career ... CVS/pharmacy or MinuteClinic. One-Stop Career Centers offer tools and training ...
... , , , N. ... Restylane(R), Perlane(R) and Juvederm(R) are popular for their ability to ... the more sensitive aesthetic patient, the possibility of experiencing injection ... improvement that could be theirs. , , ...
... , , , ... medical technology systems integrator transforming critical care, announced that former Veterans ... Board of Advisors. , , Secretary Peake retired ... and commander in several medical posts culminating in his appointment as ...
... ... in Wyoming, a subsidiary of The Eye Institute of Utah – a prominent ... practice - is the recipient of a national award recognizing the quality of ... in Utah, The Eye Institute’s Rock Springs, Wyoming location has been named by ...
... ... lifelong resident of San Antonio, is on the grow. "Bold moves are made in times ... ... Thom Robey, lifelong resident of San Antonio, is on the grow. "Bold moves are made ...
... have sex with men (MSM) in the township of Soweto in ... infected with HIV. The study,s authors were ... have sex with men in the Soweto Township, an area on ... The researchers found that Soweto MSM identified themselves as ...
Cached Medicine News:Health News:CVS Caremark to Provide $3 Million in Free Flu Shots to the Unemployed 2Health News:CVS Caremark to Provide $3 Million in Free Flu Shots to the Unemployed 3Health News:Painless, Bruise-free Dermal Filler Injections 2Health News:Former Veterans Affairs Secretary Joins Integrated Medical Systems' Advisory Board 2Health News:Former Veterans Affairs Secretary Joins Integrated Medical Systems' Advisory Board 3Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 3Health News:REES Announces New San Antonio Office 2Health News:High HIV infection rate among Soweto Township gays 2
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces the reporting of data from ... Hydrochloride for Injection with the Delcath Hepatic Delivery ... presentation at the Society of Surgical Oncology (SSO) ...
(Date:3/26/2015)... 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" ... focus on Omega-3 therapies for cardiovascular disease and overall ... 763,752 common shares of the Corporation (the "Common Shares"). ... period of December 5 th , 2014 to March ... that is due on or before April 1, 2015. ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
Breaking Medicine Technology:Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3
... , MOUNTAIN VIEW, Calif., Dec. 14 Alexza Pharmaceuticals, ... submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) ... is an inhalation product candidate being developed for the rapid ... The IND for Staccato loxapine was filed ...
... , DENVER, Dec. 14 Corgenix Medical Corporation (OTC ... diagnostic test kits, and BG Medicine, Inc. (BGM), a ... agreement whereby Corgenix will manufacture BGM Galectin-3 diagnostic products ... BG Medicine. BG Medicine is seeking regulatory clearance in ...
Cached Medicine Technology:Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM) 2
This design features a solid red iris....
This pattern transform your pupils into narrow slits surrounded by eye stopping yellow. Works well with kitty-cat costumes....
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medicine Products: